Peptide compounding rules draw a call for real trials before wider access
A Berkshire Eagle column urges the FDA to hold back injectable peptides until controlled human trials exist. An FDA panel backed six peptides in July, but none is an approved drug and key dates remain unconfirmed.
Who feels it
-
Pharmacies
Adjust
A listing would give 503A pharmacies a legal route, but the final FDA step and its conditions are not yet public.
-
Patients
Worth knowing
Pharmacy access to some peptides may widen, but they stay unapproved and human evidence for most of them is thin.
-
Prescribers
Worth knowing
Prescribing these compounded peptides means leaning on cell and animal data, with few controlled human trials to guide use.
-
Sellers
Worth knowing
Unlicensed online sellers gain no legal cover from the July vote or the HHS step, and contamination concerns remain.
-
Payers
Passes by
—
Peptide compounding rules in the United States are loosening, and an opinion column in The Berkshire Eagle argues they are loosening too fast. Published on November 6, the piece asks the FDA to hold off on more injectable peptides until proper human trials exist. It comes days after HHS Secretary Robert F. Kennedy Jr. moved on October 28 to widen access to unapproved peptide injections, according to the column. This explainer covers what has changed, what the column claims, and what is still unknown about who can get these products.
How the 503A bulks list decides what pharmacies may mix
The 503A bulks list names the raw drug ingredients that state licensed compounding pharmacies may use to mix medicines for individual patients. A peptide that is neither on that list nor part of an approved drug generally cannot be compounded lawfully, which is why many products reach buyers through unlicensed channels instead. Before an ingredient is added, the column explains, the FDA has to weigh whether there is a real clinical need for pharmacies to use it rather than an approved finished product. That test matters here because peptides such as BPC 157 have no approved version at all. Making a peptide legal to compound would not turn it into an FDA approved drug with proven benefit, a checked label and a known safety record.
At its meeting on July 23 and 24, 2026, the FDA Pharmacy Compounding Advisory Committee reviewed seven popular peptides and backed six of them for the list, according to a Holland and Knight legal analysis. The votes were split, and emideltide was the only one of the seven the panel did not recommend. An advisory vote is advice, not a final rule. The column says the same committee will weigh five more peptides by February 2027, and it accuses members of conflicts of interest tied to business dealings. Peptide Town could not confirm a meeting date, the five names or the conflict claims. The timeline below separates the steps on record from those that rest only on the column.
| Date | Step | Status |
|---|---|---|
| July 23 to 24, 2026 | FDA advisory committee reviews seven peptides | Six recommended for the 503A list, emideltide not recommended |
| October 28, 2026 | HHS Secretary Kennedy acts to widen access to unapproved peptide injections | Column says FDA scientists advised against it |
| November 6, 2026 | Berkshire Eagle column urges the FDA not to approve these peptides | Opinion, not a rule |
| By February 2027 | Same committee to consider five more peptides | Column claim, no date confirmed |
What the column says about BPC 157 and the evidence
The column singles out BPC 157, which it says influencers market as the Wolverine peptide, after the X Men character who heals almost at once. Promoters credit it with healing ulcers, repairing muscle and tendon, regrowing nerves, slowing brain decline and shielding organs from injury. The column quotes Dr. Jack Spittler, a family and sports medicine specialist and associate professor at the University of Colorado Anschutz School of Medicine, who said: "There's no miracle product out there that's going to do all these things." According to the column, most research so far comes from cell cultures and small animals. The few human studies, it says, were small and loosely run, with no blinding and no placebo groups to compare against.
Making a peptide legal to compound would not turn it into an FDA approved drug with proven benefit, a checked label and a known safety record.
That evidence gap is the core of the Berkshire Eagle opinion column. Spittler is quoted as saying there is "basically zero" evidence from human trials and that "we just don't know how they affect the human body." The column also cites Harvard Health Publishing, which has written that the benefits and risks of injectable peptides popular on social media are largely unknown. Its ask is specific: randomized, placebo controlled trials for named diagnoses, standardized manufacturing, independent checks of purity, potency, sterility and stability, and ongoing safety monitoring. Our earlier report on BPC 157 human proof found that a first controlled patient trial is still only planned, so that demand is far from met.
The gray market risks behind unregulated peptide injections
Beyond the debate over peptide compounding rules, the column lists the harms it fears from injecting peptides. They could set off abnormal immune responses, leading to allergic reactions and autoimmune problems. Products may carry impurities, a risk the column ties mostly to gray market peptides and black market injectables. It also names stomach upset such as nausea, diarrhea and constipation, along with headaches, tiredness and irritation where the needle goes in. Long term effects, it says, are unknown. The piece adds that many online promoters have no medical training, so buyers may not grasp what they are taking. It calls young people especially exposed, because they spend more time in online enhancement culture and may judge risk less well.
This is where the rules and the market meet. A licensed pharmacy that compounds a listed peptide must answer to state boards and federal sourcing rules, while a website shipping unlabeled vials answers to no one. Peptide compounding rules can move some demand toward the first channel, but they do nothing to clean up the second. Regulators abroad face the same problem. In Australia, the medicines regulator has seized more than 94,500 products this year, and an ABC investigation traced sales to paid influencer campaigns for factory made peptides. None of the steps taken in Washington this year makes an unlicensed seller legal, and none tests what is inside an unmarked vial.
What is still unknown about access and timing
The October 28 move is the part of the story with the most open ends. The column says Kennedy acted on his own and bypassed FDA safeguards, even though the FDA has the final say on changes to the list, and that FDA scientists had advised against the step. Those are the columnist's words. Our report on the HHS peptide policy found that HHS will not pursue small 503A pharmacies that compound BPC 157 and five other unapproved peptides. Larger outsourcing facilities are left out, and a start date had not been made clear at the time of that report. An enforcement stance like this is a choice not to act against pharmacies, and it can be changed without a new law.
Several questions decide who can actually get these peptides and on what terms. The FDA has not yet taken a final step to add the six recommended peptides to the list, and no conditions for that step are public. The five further peptides the column mentions have not been named, and no meeting date for them has been confirmed. It is also unclear how state pharmacy boards will treat compounded peptides while federal policy shifts. Until those points are settled, peptide compounding rules will keep changing in steps, and patients will be choosing products with thin human data behind them. Readers weighing these products should treat every claim of benefit with care and talk to a licensed clinician first.
Conclusion
The Berkshire Eagle column adds no new rule, but it sets out the main concern behind this year's shift in peptide compounding rules: access is widening faster than human evidence. The FDA committee vote in July and the HHS step in October make pharmacy compounding more likely. Neither makes any of these peptides an approved drug, and neither touches the gray market. This story is for research and news purposes only and is not medical advice.
Source Opinion column, The Berkshire Eagle, November 6, 2026; Holland and Knight analysis of the July 23 to 24, 2026 FDA Pharmacy Compounding Advisory Committee meeting
Sources
Spotted an error? Tell us through the contact form; we follow the corrections policy.